IL-4 Implicated in CAR-T Cell Therapy Resistance

Mayo Clinic researchers have made a significant discovery in understanding why chimeric antigen receptor (CAR-T) cell therapy fails in some cancer patients. Led by Saad Kenderian, the team identified an overproduction of the interleukin-4 (IL-4) protein as a key factor in CAR-T cell exhaustion, which leads to treatment failure.

The study, published in Nature Communications, compared CAR-T cells from patients who achieved remission with those whose treatment failed. They also analyzed tumor responses in laboratory mice. In both human and animal samples, elevated levels of IL-4 were associated with CAR-T cell exhaustion.

While IL-4 typically activates the immune system against cancer, the research showed that excessive production by supercharged CAR-T cells can overwhelm and exhaust them. This discovery opens new avenues for improving CAR-T cell therapy's longevity and effectiveness.

Using CRISPR gene-editing technology, the team successfully removed the IL-4 protein from dysfunctional CAR-T cells, enhancing their ability to recognize and destroy cancer cells. Additionally, monoclonal antibodies were tested to neutralize the IL-4 protein, also showing promise in rejuvenating CAR-T cells.

This research offers new hope for overcoming the challenges faced by many cancer patients undergoing CAR-T cell therapy. By addressing the mechanism of resistance, Mayo Clinic researchers have paved the way for potential improvements in this revolutionary treatment, potentially benefiting more patients with blood cancers like B-cell lymphomas and leukemias.